Dr. Phillips Discusses the Treatment of ATLL

Adrienne Phillips, MD, MPH
Published: Tuesday, Feb 11, 2014

Adrienne Phillips, MD, MPH, assistant professor of clinical medicine, Columbia University Medical Center, discusses advances in the treatment of HTLV-related adult T-cell leukemia lymphoma.

Traditionally, patients with this disease have been treated with the same chemotherapies used in other aggressive lymphomas such as CHOP and EPOCH. Unfortunately, though these regimens produce high response rates, responses seen are not durable.

One trial is looking at a combination of standard chemotherapy, bortezomib, and raltegravir, an antiviral agent. Another trial is analyzing an anti-CCR4 therapy, which has shown promise in Japan, Phillips says.

Adrienne Phillips, MD, MPH, assistant professor of clinical medicine, Columbia University Medical Center, discusses advances in the treatment of HTLV-related adult T-cell leukemia lymphoma.

Traditionally, patients with this disease have been treated with the same chemotherapies used in other aggressive lymphomas such as CHOP and EPOCH. Unfortunately, though these regimens produce high response rates, responses seen are not durable.

One trial is looking at a combination of standard chemotherapy, bortezomib, and raltegravir, an antiviral agent. Another trial is analyzing an anti-CCR4 therapy, which has shown promise in Japan, Phillips says.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x